Baxter Healthcare is expanding its European R&D presence with a new facility designed to take new pharmaceuticals from “conception to registration.”
The unit, in Alliance Park Braine l'Alleud, south of Brussels, Belgium, will act as Baxter’s hub for development of recombinant, plasma-based therapeutics, vaccines, packaging and delivery systems and peritoneal dialysis devices.
Baxter has operated in Belgium for fifty years, previously basing its R&D operations in Nivelles and the capital Brussels. However, according to company vice president Ludwig Hantson, the new unit offers a number of advantages.
“Alliance Park provides a critical step forward in Baxter's future by aligning multiple functions in one area, thereby encouraging more ideas to develop into solutions that serve healthcare professionals and patients."